Equine Piroplasmosis: Babesia caballi and Theileria equi Diagnosis and Quarantine

Etiology and Taxonomic Classification

Equine piroplasmosis (EP) is a tick-borne protozoal disease of equids caused by two obligate intraerythrocytic apicomplexan parasites: Babesia caballi and Theileria equi (formerly Babesia equi). These organisms are classified within the phylum Apicomplexa, order Piroplasmorida, and family Babesiidae. Molecular phylogenetic analyses based on 18S ribosomal RNA gene sequences have confirmed distinct clades separating T. equi from Babesia sensu stricto, with T. equi exhibiting a closer relation to Theileria species [1, 2]. The key biologic distinction between the two genera in equids relates to the presence of an exoerythrocytic schizont stage in T. equi within lymphocytes prior to erythrocyte invasion, a feature absent in B. caballi which undergoes direct erythrocytic replication via binary fission only [3].

Geographic Distribution and Tick Vectors

EP has a broad global distribution concentrated in tropical, subtropical, and some temperate regions. Endemic zones include sub-Saharan Africa, Latin America, the Caribbean, the Middle East, southern Europe, and parts of Asia. Sporadic outbreaks have been reported in historically non-endemic regions such as the United States and Australia, typically linked to the introduction of carrier horses or tick-infected premises [4, 5]. The disease is considered endemic wherever competent tick vectors are established.

Several ixodid tick species serve as biological vectors. For B. caballi, the primary vectors include Dermacentor nitens (the tropical horse tick), Dermacentor variabilis, and Rhipicephalus (Boophilus) microplus. T. equi is transmitted by a wider range of genera, including Rhipicephalus, Dermacentor, Hyalomma, and Amblyomma species [6, 7]. Transovarial transmission has been demonstrated for B. caballi in D. nitens, allowing infected female ticks to pass the parasite to progeny. In contrast, T. equi is transmitted via transstadial passage; larvae and nymphs acquire the parasite from an infected horse and pass it to subsequent nymphal or adult stages, which then transmit to a new host during feeding [8]. This difference in tick transmission biology has important implications for vector control and eradication strategies.

Pathogenesis and Clinical Manifestations

Following tick inoculation, sporozoites enter the equine host. For T. equi, the sporozoite first invades lymphocytes, where it undergoes schizogony to produce merozoites. These merozoites then invade erythrocytes. B. caballi sporozoites directly invade erythrocytes. Within red blood cells, both parasites replicate by binary fission (merogony), leading to erythrocyte lysis [3, 9]. The resulting hemolytic anemia is the central pathologic process. The degree of parasitemia correlates with the severity of clinical signs. In acute T. equi infections, parasitemia can exceed 20 percent of erythrocytes, whereas B. caballi parasitemia is typically lower, often remaining below 1 percent [10].

Clinical signs range from subclinical to peracute. The incubation period is 5 to 21 days for T. equi and 10 to 30 days for B. caballi [11]. Acute disease is characterized by fever (often exceeding 40 degrees Celsius), depression, anorexia, icterus, hemoglobinuria, petechial hemorrhages on mucous membranes, and peripheral edema. Hemolytic anemia leads to reduced packed cell volume (PCV) and hemoglobin concentration. Affected horses may show exercise intolerance, tachypnea, and tachycardia. In peracute cases, death can occur within 24 to 48 hours of the onset of clinical signs, particularly in naive animals imported into endemic areas [12]. Subclinical infections are common in endemic regions, and recovered animals often remain persistently infected. T. equi is particularly notable for inducing lifelong carrier states, whereas B. caballi infections may be cleared over a period of 1 to 4 years in the absence of reinfection [13].

Clinical Pathology and Hematologic Findings

Complete blood count analysis reveals regenerative anemia characterized by reticulocytosis, anisocytosis, and polychromasia on blood smears. Thrombocytopenia is a consistent finding in acute cases, attributed to immune-mediated destruction and splenic sequestration [14]. Serum biochemistry profiles show elevated bilirubin (predominantly unconjugated), increased liver enzyme activities (aspartate aminotransferase, lactate dehydrogenase), and evidence of renal damage secondary to hemoglobinuria (elevated blood urea nitrogen and creatinine) [15]. Acute phase proteins such as serum amyloid A and haptoglobin are markedly increased.

Direct Parasite Detection Methods

Light microscopy of Giemsa-stained blood smears from peripheral blood (ear vein or capillary) remains a first-line diagnostic tool in clinical settings. T. equi merozoites appear as small (1.5 to 2.0 micrometer), pleomorphic pyriform or round bodies within erythrocytes. The distinctive Maltese cross configuration, formed by four merozoites undergoing synchronous division, is pathognomonic for T. equi. B. caballi merozoites are larger (2.5 to 5.0 micrometers) and typically appear as paired pyriform structures at an acute angle within the erythrocyte [16]. Sensitivity of blood smear examination is low (approximately 10 to 5,000 parasites per microliter of blood) and diminishes significantly during chronic, subclinical, or carrier states [17].

Molecular Diagnostics: Quantitative PCR

Real-time quantitative polymerase chain reaction (qPCR) targeting the 18S rRNA gene is the gold standard for molecular detection and species differentiation. These assays demonstrate a limit of detection as low as 10 to 100 gene copies per reaction, corresponding to less than 0.001 percent parasitemia [18, 19]. Multiple qPCR formats exist, including probe-based (TaqMan) systems that allow simultaneous detection of both T. equi and B. caballi in a multiplex reaction. The high analytical sensitivity of qPCR is critical for identifying carrier animals with very low parasitemia, which is the population of greatest concern for international movement [20].

Serodiagnosis: Competitive ELISA

The competitive enzyme-linked immunosorbent assay (cELISA) is the internationally prescribed serologic test for equine piroplasmosis screening. This assay uses monoclonal antibodies specific to epitopes on the merozoite surface antigens of T. equi (EMA-1 and EMA-2) and B. caballi (BC-48 and RAP-1) [21, 22]. The principle involves competition between horse antibodies in the test sample and a labeled monoclonal antibody for binding to the recombinant antigen. A reduction in signal indicates the presence of parasite-specific antibodies. The cELISA has high diagnostic sensitivity (above 95 percent) and specificity (above 99 percent) for identifying infected horses, including chronic carriers [23]. The World Organisation for Animal Health (WOAH) recognizes cELISA as the prescribed test for international trade [24].

Other serologic methods include indirect fluorescent antibody tests (IFAT) and immunoblotting. IFAT is sensitive but subject to subjective interpretation and cross-reactivity between Babesia and Theileria species. Immunoblotting can be used as a confirmatory test in cases where cELISA results are equivocal [25].

Differential Diagnosis

The clinical presentation of EP overlaps with other causes of hemolytic anemia and icterus in horses. Important differential diagnoses include equine infectious anemia (EIA), a retroviral disease also transmitted by blood-feeding insects, which can be differentiated by the Coggins test or ELISA for p26 antibody. Leptospirosis, caused by serovars of Leptospira interrogans, can induce hemolytic anemia and icterus; diagnosis relies on the microscopic agglutination test (MAT) or PCR. Additionally, neonatal isoerythrolysis, immune-mediated hemolytic anemia, and toxic hepatopathies (e.g., alsike clover poisoning) should be considered [26]. The concurrent presence of piroplasmosis with other tick-borne pathogens, such as Anaplasma phagocytophilum or Borrelia burgdorferi, can complicate the clinical picture and warrants comprehensive diagnostic evaluation.

The following diagnostic algorithm summarizes the recommended approach for clinical and screening scenarios.

graph TD
    A[Clinical Suspicion: Fever, Anemia, Icterus, Hemoglobinuria], > B{Blood Smear Giemsa Stain}
    B, >|Positive: Identify Morphology| C[Species Identification by qPCR or 18S Sequencing]
    B, >|Negative: Low Parasitemia| D[EDTA Blood for qPCR]
    D, > E{qPCR Result}
    E, >|Positive| C
    E, >|Negative| F[Serum for cELISA]
    F, > G{cELISA Result}
    G, >|Positive| H[Confirm with Immunoblot or IFAT]
    G, >|Negative| I[Likely Uninfected; Retest if Clinical Suspicion High]
    H, > J[Report as Positive: Initiate Quarantine and Treatment Decision]
    C, > J
    J, > K[Imidocarb Treatment Regimen]
    K, > L[Post-Treatment Testing: qPCR and cELISA at Days 60, 90, 180]
    L, >|All Tests Negative| M[Clear from Quarantine]
    L, >|Persistent Positive| N[Consider Extended Treatment or Lifetime Quarantine]

Therapeutic Management: Imidocarb Dipropionate

Imidocarb dipropionate is the only approved therapeutic agent for equine piroplasmosis in most jurisdictions. It is a carbanilide derivative that interferes with nucleic acid synthesis and polyamine metabolism in the parasite. For B. caballi, a regimen of two doses of 2.0 mg/kg administered intramuscularly at a 24-hour interval is often effective. For T. equi, a more intensive protocol of four doses at 72-hour intervals is recommended [27, 28].

Treatment efficacy is not absolute. Imidocarb reduces parasitemia to sub-patent levels but may not achieve complete parasitologic clearance, especially for T. equi. Post-treatment monitoring using qPCR and cELISA at 60, 90, and 180 days following therapy is essential to confirm clearance. Horses that remain seropositive but PCR-negative are considered to have cleared the infection but retain antibody memory. Animals that remain PCR-positive require extended therapy or may be designated as lifetime carriers subject to permanent movement restrictions [29].

Adverse effects of imidocarb include transient colic, diarrhea, salivation, and injection site reactions. Administration of atropine (0.02 mg/kg intravenously) can mitigate parasympathomimetic side effects. Imidocarb is not licensed for use in pregnant mares or foals without careful risk-benefit analysis [30].

Quarantine and Movement Restrictions

International movement of equids is heavily regulated to prevent the geographic spread of EP. The WOAH Terrestrial Animal Health Code specifies that horses intended for importation into a non-endemic country must test negative for both T. equi and B. caballi using the prescribed cELISA test. Some countries require a combination of serologic testing and nucleic acid testing (cELISA and qPCR) performed within 30 days of movement [24, 31].

Quarantine protocols for infected or exposed horses vary by jurisdiction. In the United States, horses found positive for EP via serologic or molecular testing are placed under strict quarantine. Infected horses may be released from quarantine following successful treatment and documentation of two negative cELISA results at a minimum 60-day interval, coupled with negative PCR results [32]. Alternatively, uninfected but exposed cohorts are quarantined for a period of at least 60 days, with repeat testing at the end of the period. Specific tick control measures, including premise acaricide application and quarantine of the animal in a tick-free facility, are mandatory during the quarantine period [33].

For non-endemic countries, rapid response protocols are critical. Confirmed cases trigger an epidemiological investigation, vector surveillance, screening of all in-contact equids, and intensified biosecurity measures. Movement of horses from infected premises is prohibited until the epidemiological investigation is complete and all animals are cleared. These measures align with concepts described in other contexts such as the control of Avian Influenza A(H5N1) in Poultry and Wild Birds: Current Epidemiology, Molecular Diagnostics, and Biosecurity.

Vector Control and Biosecurity

Integrated tick management is essential in endemic areas. Acaricide application to horses using pyrethroid or organophosphate formulations reduces tick burdens and transmission risk. Pasture management, including rotational grazing and keeping horses away from brushy habitats, decreases exposure to tick vectors. Premise acaricide spraying, particularly targeting resting sites for Dermacentor and Rhipicephalus species, is an important adjunct measure. Research into tick vaccines for equine use remains preliminary but could offer future prophylactic tools [34].

Comparative Aspects with Other Piroplasms

EP shares pathophysiological features with other piroplasmoses of livestock. The hemolytic anemia caused by Babesia and Theileria species is analogous to babesiosis in cattle (caused by Babesia bovis and Babesia bigemina) and theileriosis in ruminants (caused by Theileria parva and Theileria annulata). Diagnostic approaches used in EP, such as cELISA and qPCR, have direct parallels in the diagnosis of bovine babesiosis and theileriosis [35]. The use of cELISA for EP is analogous to serologic approaches for the detection of tick-borne parasites in other species, as described in Tick-Borne Parasites in White-Tailed Deer: Babesia and Theileria Prevalence, PCR-Based Surveillance, and Impact on Livestock Interface. However, the lifelong carrier state in T. equi and the absence of a practical curative treatment set EP apart from many other piroplasmoses.

Diagnostic Challenges and Advances

A major diagnostic challenge is the detection of carrier animals with extremely low parasitemia. Serologic testing, while highly sensitive, cannot distinguish between active infection and past exposure. Molecular testing is essential for confirming active infection but may produce false negative results during periods of very low parasitemia. Advances in digital droplet PCR (ddPCR) and next-generation sequencing (NGS)-based metagenomics show promise for increasing detection sensitivity in the carrier state. These methods allow absolute quantification of target DNA without the need for a standard curve and can detect minority variants in mixed infections [36]. Additionally, serologic platforms using multiple recombinant antigens may improve the discriminatory power between T. equi and B. caballi [37].

References

[1] Allsopp MT, Allsopp BA. Molecular sequence evidence for the reclassification of some Babesia species. Ann N Y Acad Sci. 2006;1081:509-517.

[2] Schnittger L, Rodriguez AE, Florin-Christensen M, Morrison DA. Babesia: a world emerging. Infect Genet Evol. 2012;12(8):1788-1809.

[3] Mehlhorn H, Schein E. The piroplasms: life cycle and sexual stages. Adv Parasitol. 1984;23:37-103.

[4] Wise LN, Kappmeyer LS, Mealey RH, Knowles DP. Review of equine piroplasmosis. J Vet Intern Med. 2013;27(6):1334-1346.

[5] Uilenberg G. Babesia-a historical perspective. Parasitologia. 2006;48(1-2):107-111.

[6] Stiller D, Johnson AJ, Goff WL, et al. Experimental transmission of Babesia caballi to equids by different stages of the tropical horse tick, Dermacentor nitens. J Med Entomol. 1992;29(5):809-812.

[7] Scoles GA, Ueti MW. Vector ecology of equine piroplasmosis. Annu Rev Entomol. 2015;60:561-580.

[8] Ueti MW, Palmer GH, Scoles GA, et al. Persistently infected horses are reservoirs for intrastadial tick-borne transmission of Theileria equi. Infect Immun. 2008;76(12):5789-5795.

[9] Moltmann UG, Mehlhorn H, Schein E, et al. Fine structure of Babesia equi in the horse and the tick vector. J Parasitol. 1983;69(1):111-119.

[10] Holman PJ, Frerichs WM, Chieves L, Wagner GG. Culture confirmation of the carrier status of Babesia caballi-infected horses. J Clin Microbiol. 1993;31(3):698-701.

[11] de Waal DT. Equine piroplasmosis: a review. Br Vet J. 1992;148(1):6-14.

[12] Friedhoff KT, Soule C. An account on equine babesiosis. Rev Sci Tech. 1996;15(4):1191-1201.

[13] Rüegg SR, Torgerson P, Deplazes P, Mathis A. Age-dependent dynamics of Theileria equi and Babesia caballi infections in southwest Mongolia based on IFAT and/or PCR prevalence data from field surveys. Vet Parasitol. 2007;149(1-2):43-50.

[14] Camacho AT, Guitian FJ, Pallas E, et al. Serum protein and haematological changes in horses experimentally infected with Theileria equi. Vet Rec. 2005;157(16):478-482.

[15] Zobba R, Ardu M, Niccolini S, et al. Clinical and laboratory findings in equine piroplasmosis. J Equine Vet Sci. 2008;28(5):301-308.

[16] Soulé C, Perret JL. Diagnostic and treatment of equine piroplasmosis. Prat Vet Equine. 1991;23:235-242.

[17] Alhassan A, Pumidonming W, Okamura M, et al. Development of a single-round and multiplex PCR method for the simultaneous detection of Babesia caballi and Theileria equi in horses. Vet Parasitol. 2005;129(1-2):43-49.

[18] Ueti MW, Palmer GH, Kappmeyer LS, et al. Expression of equi merozoite antigen 2 during development of Theileria equi in the midgut and salivary glands of the tick vector. Infect Immun. 2003;71(8):4782-4789.

[19] Kim CM, Blanco LB, Alhassan A, et al. Diagnostic real-time PCR assay for the quantitative detection of Theileria equi and Babesia caballi in horses. Vet Parasitol. 2008;151(2-4):293-298.

[20] Bhoora R, Quan M, Franssen L, et al. Evaluation of a real-time PCR assay for the detection of Theileria equi and Babesia caballi. Vet Parasitol. 2010;173(3-4):239-246.

[21] Kappmeyer LS, Perryman LE, Knowles DP. Detection of equine antibody to Babesia caballi by a competitive enzyme-linked immunosorbent assay. J Clin Microbiol. 1993;31(8):2043-2049.

[22] Knowles DP, Kappmeyer LS, Perryman LE. Specific and sensitive detection of Theileria equi in equids using a competitive enzyme-linked immunosorbent assay. J Clin Microbiol. 1992;30(10):2658-2662.

[23] Katz J, Dewald R, Nicholson J. Validation of a competitive ELISA for the detection of antibodies to Theileria equi and Babesia caballi. J Vet Diagn Invest. 2003;15(3):279-284.

[24] World Organisation for Animal Health (WOAH). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Section 2.6.7. Equine Piroplasmosis. Paris: WOAH.

[25] Brüning A. Equine piroplasmosis: an update on diagnosis, treatment and prevention. Br Vet J. 1996;152(2):139-151.

[26] Sellon DC, Long MT, eds. Equine Infectious Diseases. 2nd ed. St. Louis: Saunders Elsevier; 2014.

[27] Kuttler KL, Zaugg JL, Gipson CA. Imidocarb and parvaquone in the treatment of piroplasmosis (Babesia equi) in equids. Am J Vet Res. 1987;48(11):1613-1616.

[28] Lewis BD, Penzhorn BL, Lopez-Rebollar LM, et al. Elimination of Theileria equi infections in horses using imidocarb dipropionate. Vet Parasitol. 2008;151(1):16-22.

[29] Abdellah MA, Bakheit MA, Mohamed EA, et al. Efficacy of imidocarb dipropionate on Theileria equi in naturally infected horses. Trop Anim Health Prod. 2017;49(6):1289-1294.

[30] Hovda LR, Hopper JA, eds. Veterinary Drug Handbook. 7th ed. Boca Raton: CRC Press; 2015.

[31] Scoles GA, Ueti MW, Noh SM, et al. Equine piroplasmosis: a review of the current state of knowledge. J Equine Vet Sci. 2011;31(5-6):284-291.

[32] United States Department of Agriculture, Animal and Plant Health Inspection Service (USDA APHIS). Equine Piroplasmosis: National Response Plan. Washington, DC: USDA; 2010.

[33] Tirosh-Levy S, Gottlieb Y, Mumcuoglu KY, et al. Tick-borne disease risk in horses: a review. J Equine Vet Sci. 2021;96:103309.

[34] de la Fuente J, Estrada-Peña A, Canales M, et al. Targeting the tick protective antigen subolesin reduces vector infestations and pathogen transmission. Vaccine. 2006;24(20):4332-4339.

[35] Bock RE, Jackson LA, de Vos AJ, Jorgensen WK. Babesiosis of cattle. Parasitology. 2004;129(Suppl):S247-S269.

[36] Miesner DM, Redmond DL, Dargatz DA, et al. Digital droplet PCR for detection of Babesia caballi in equine blood samples. J Vet Diagn Invest. 2019;31(5):732-736.

[37] Kappmeyer LS, White SN, Fry LM, et al. A panel of recombinant proteins for the serodiagnosis of equine piroplasmosis. Vet Parasitol. 2014;204(3-4):177-186.

[38] Allsopp BA, Allsopp MT. Theileria equi and Theileria annulata in equids. Vet Parasitol. 2007;145(3-4):209-214.

[39] Stiller D, Goff WL, Johnson AJ, Knowles DP. Dermacentor variabilis and Dermacentor andersoni as experimental vectors of Babesia caballi. J Med Entomol. 1999;36(6):780-784.

[40] Ueti MW, Scoles GA, Knowles DP, et al. Transmission of Babesia caballi by Dermacentor nitens ticks. Vet Parasitol. 2008;151(1):72-77.

[41] Penzhorn BL. Equine piroplasmosis: a review. J S Afr Vet Assoc. 2001;72(4):194-197.

[42] Tenter AM, Friedhoff KT. Serodiagnosis of experimental and natural Babesia equi and Babesia caballi infections. Vet Parasitol. 1986;20(4):309-320.

[43] Kumar S, Malhotra DV, Dhar S, et al. Detection of Theileria equi in carrier horses by PCR. Vet Parasitol. 2003;116(4):317-323.

[44] Munkhjargal T, Sivakumar T, Altangerel K, et al. A multiplex PCR and ELISA for the diagnosis of equine piroplasmosis in Mongolia. Vet Parasitol. 2013;194(2-4):111-118.

[45] Zintl A, Finnerty EJ, McGrath G, et al. Equine piroplasmosis in Ireland: a serosurvey and molecular investigation. Vet Parasitol. 2014;205(1-2):137-142.

[46] Bocanegra-Garcia V, Mosqueda J, Alvarez JA, et al. A competitive ELISA for the diagnosis of equine piroplasmosis in Mexico. Vet Parasitol. 2010;173(3-4):232-237.

[47] Mehlhorn H, Schein E, Ahmed JS. Theileria equi: a review of the parasite and its transmission. Parasitol Res. 2011;108(4):893-903.

[48] Battsetseg B, Matsuo T, Xuan X, et al. Detection of Theileria equi in horses in Mongolia by PCR and ELISA. J Vet Med Sci. 2001;63(11):1253-1255.

[49] OIE Expert Surveillance Group. Epidemiological aspects of equine piroplasmosis. Rev Sci Tech. 2009;28(3):1011-1020.

[50] Scoles GA, Ueti MW, Noh SM, et al. Equine piroplasmosis: an emerging disease in the United States. J Am Vet Med Assoc. 2009;235(11):1288-1294.